Wat is de prijs voor Jiangsu Yahong Meditech Co Ltd (688176)

Het prijs van Jiangsu Yahong Meditech Co Ltd (688176) is $1.72

Wat is de marktkapitalisatie voor Jiangsu Yahong Meditech Co Ltd (688176)

Marktkapitalisatie voorJiangsu Yahong Meditech Co Ltd (688176) is $985.07M

Jiangsu Yahong Meditech Co Ltd (688176) K/O-verhouding

Established in 2010 and headquartered in Shanghai, China, Jiangsu Yahong Meditech Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutic drugs. Its primary focus lies in medicines targeting genitourinary system cancers, though its pipeline extends to a variety of other diseases, serving both domestic Chinese and international markets. The company's clinical-stage pipeline features several key candidates. Notably, two compounds, APL-1202 (an anti-tumor drug) and APL-1706 (an agent drug), are both undergoing Phase III trials for the treatment of non-muscle invasive bladder cancer. Another promising candidate, APL-1501, an oral MetAP inhibitor, is currently in Phase I testing for addressing urinary system tumors and drug-resistant urinary tract infections. Furthermore, APL-1702, a photodynamic therapy product, is in Phase III for tackling cervical high-grade squamous intraepithelial lesions that arise from HPV infections. Beyond these clinical programs, Jiangsu Yahong Meditech is actively exploring targeted protein degraders in its preclinical phase. This includes ASN-1764, aimed at triple-negative breast cancer; ASN-1780, intended for metastatic castration-resistant prostate cancer; and APL-1901, designed to treat ER-positive breast cancer. The company's developmental efforts also encompass APL-1401, targeting moderately to severely active ulcerative colitis, and ASN-1733, for combating Acinetobacter baumannii infection.

Jaar	P/S-ratio	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

P/S-ratio

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	P/S-ratio	Verschil in P/S-ratio	Land
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	7.73	-	IN

Bedrijf

P/S-ratio

Verschil in P/S-ratio

Land